Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Sanofi bets on AI-powered decision making

By Brian Buntz | June 15, 2023

Sanofi logoUnveiling Sanofi’s AI-powered pharma strategy, the French pharma giant announced its plans to tap AI for insights across the company. With “plai,” an internal app, AI could provide real-time data supporting decision-making.

Sanofi’s goal, as CEO Paul Hudson stated in a news release, is to become the first pharma company powered by AI at scale, “giving our people tools to make better everyday decisions.”

How Sanofi’s AI-powered pharma strategy compares to other industry moves

Several other companies have initiated similar AI-powered moves over the years. For instance, in December 2016, Pfizer and IBM inked a deal to use IBM Watson for drug discovery in immuno-oncology. Roche has explored using machine learning for diabetes diagnostics while companies like Novartis have advertised hundreds of AI hires in recent years.

Challenges of AI in healthcare and Sanofi’s AI-powered pharma strategy

Yet, deploying AI in healthcare settings often poses challenges. Consider the case of IBM Watson, which shone on Jeopardy in 2011 but faced struggles in healthcare and the commercial world later.
Nevertheless, AI systems have grown more robust in recent years. Gartner estimated that AI software revenue is growing at roughly 20% annually. Market growth is expected to accelerate as organizations progress with their AI maturity.

Sanofi’s “plai” to rethink pharma

Sanofi’s AI-powered pharma strategy involves “plai,” an app developed with AI startup Aily Labs. It offers personalized predictive analytics and scenarios to guide company-wide choices.
In late 2022, Sanofi unveiled a new Paris headquarters. The company has steadily ramped up its focus on AI in recent years. Late 2021 saw Sanofi planning to acquire Amunix for its AI empowering smart tumor-only drug delivery and investing in Exscientia after five years of partnership on AI for drug discovery. Furthermore, Sanofi has inked partnership deals with Insilico, Atomwise, and Owkin on AI for drug development. “We’ve only scratched the surface of how AI can transform medicine,” Hudson expressed.

The impact of Sanofi’s AI-powered pharma strategy and its industry comparison

Sanofi isn’t alone in its AI focus. Companies like Eli Lilly, Boehringer Ingelheim, Click Therapeutics, Novartis, J&J, AZ, BMS, GSK, Bayer, and Takeda are also making significant AI moves. Notably, Takeda has invested heavily in AI to speed up drug discovery, claiming that the technology helped identify candidates in months instead of years.
Indeed, AI can be challenging for pharma. “Black box” models yield game-changing insights but lack transparency, causing concern. Some of the most accurate ML algorithms have traditionally been the most puzzling for humans to comprehend.

The potential of AI in drug development

The potential of AI in drug development, particularly in strategies like Sanofi’s AI-powered pharma, is becoming increasingly apparent. When these complex models work, they expedite the drug discovery process, accelerate time-to-market, and unlock new therapeutic opportunities hidden within vast seas of data. Bloomberg labeled AI in Big Pharma as a $50 billion opportunity. Companies that successfully harness its power could significantly shorten the billion-dollar-plus and decade-plus timelines of drug development.

Embracing the Sanofi’s AI-powered pharma strategy, companies that seamlessly and ethically integrate AI into their operations could chip away at the billion-dollar-plus timelines of the decade-plus time spans of traditional drug development.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Moving toward the autonomous lab and what’s possible today
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
Genentech roche
Roche, Genentech to build $700M drug manufacturing plant in North Carolina
These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE